• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Iqirvo Data Shows Long Efficacy in PBC with Fatigue Improvement

    GLOBENEWSWIRE

    GENFIT Announces Updates & Participation at Liver Meeting® 2024

    GLOBENEWSWIRE

    Ipsen Monthly Info on Voting Rights & Share Capital (Oct 2024)

    GLOBENEWSWIRE

    Ipsen Delivers Strong Sales Momentum And Raises Guidance

    GLOBENEWSWIRE

    Ipsen receives its second Shingo Prize for operational excellence

    GLOBENEWSWIRE

    UK MHRA Grants Approval For Ipsen’s Elafibranor Treatment

    PHARMABIZ

    Ipsen - September 2024 - Monthly Information On Voting Rights

    GLOBENEWSWIRE

    Ipsen`s IQIRVO Approval Intensifies Primary Biliary Cholangitis

    PR NEWSWIRE

    Ipsen picks up EU approvals for rare disease meds Kayfanda

    GLOBENEWSWIRE

    Ipsen`s Kayfanda Approved In EU For Alagille Syndrome Pruritus

    GLOBENEWSWIRE

    EU Approves Ipsen`s Iqirvo For Biliary Cholangitis

    GLOBENEWSWIRE

    Ipsen Pharma`s Iqirvo (elafibranor) Receives Approval in Europe

    EMA

    Ipsen Pharma`s Kayfanda (odevixibat) Receives Approval in Europe

    EMA

    Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan

    FIERCE PHARMA

    Cabometyx Efficacy In Neuroendocrine Tumors Reinforced

    GLOBENEWSWIRE

    Ipsen Updates On CONTACT-02 Trial In Prostate Cancer After Final Analysis

    GLOBENEWSWIRE

    Demy-Colton`s BioFuture 2024 To Feature Regeneron, IBM, Ipsen, And VCs

    BUSINESSWIRE

    Employee of French drugmaker Ipsen to plead guilty to US insider trading

    REUTERS

    Ipsen Reports August 2024 Voting Rights And Share Capital

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

    GLOBENEWSWIRE

    Ipsen Reports July 2024 Voting Rights And Share Capital Information

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

    GLOBENEWSWIRE

    CHMP Endorses New Medicines From Astellas, J&J And Ipsen

    FIERCE PHARMA

    Ipsen Gets CHMP Nod For Iqirvo And Kayfanda In Rare Liver Diseases

    GLOBENEWSWIRE

    Ipsen And Day One Partner On Tovorafenib For Childhood Brain Tumor

    GLOBENEWSWIRE

    Ipsen Reports Strong H1 2024 Results, Upgrades Full-Year Guidance

    GLOBENEWSWIRE

    Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

    GLOBENEWSWIRE

    Ipsen Secures Ex-US Rights To Day One`s Pediatric Cancer Med For $111M

    FIERCE PHARMA

    IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

    GLOBENEWSWIRE

    Ipsen scores 2nd ADC via $1B biobucks pact with Foreseen

    PRESS RELEASE

    Ipsen And Foreseen Biotech Sign Global License For Novel ADC

    GLOBENEWSWIRE

    Ipsen scores 2nd preclinical ADC via $1B biobucks pact with Foreseen

    FIERCE BIOTECH

    Ipsen Reports June 2024 Voting Rights And Share Capital Information

    GLOBENEWSWIRE

    Half-year statement of IPSEN liquidity agreement - 2024 06 30

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

    GLOBENEWSWIRE

    Ipsen Expands Cabometyx Collaboration For Neuroendocrine Tumors

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

    GLOBENEWSWIRE

    IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

    GLOBENEWSWIRE

    US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug

    REUTERS

    Ipsen`s Iqirvo Receives Accelerated FDA Approval For Cholangitis Treatment

    GLOBENEWSWIRE

    Ipsen, Marengo ink $1.2B biobuck deal to treat cold tumors

    FIERCE BIOTECH

    Ipsen, Marengo Partner On Tri-STAR Precision T-Cell Engagers

    GLOBENEWSWIRE

    Ipsen Shares Monthly Voting Rights And Share Capital Information

    GLOBENEWSWIRE

    Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

    GLOBENEWSWIRE

    Gilead, Ipsen build the case for their PBC drugs at EASL

    PHARMAPHORUM

    Ipsen: Long-Term Elafibranor Efficacy & QoL In PBC Patients

    GLOBENEWSWIRE

    Ipsen Initiates Share Buyback For Employee Stock Plan

    GLOBENEWSWIRE

    Ipsen announces the launch of an employee shareholding plan

    GLOBENEWSWIRE

    Annual General Meeting of Ipsen S.A. held on 28 May 2024

    GLOBENEWSWIRE

    Ipsen Share Buyback Framework: For Agm Shareholder Approval Detailed

    GLOBENEWSWIRE

    FDA denies Ipsen`s citizen petition for blockbuster drug Somatuline

    ENDPTS

    Ipsen Preps For 2024 Annual General Meeting Document Availability

    GLOBENEWSWIRE

    Ipsen Shares, Voting Rights Composition Monthly Update

    GLOBENEWSWIRE

    Ipsen appoints Keira Driansky as EVP, President of North America

    GLOBENEWSWIRE

    Ipsen matches rare disease and TikTok influencers to create connections

    ENDPTS

    Ipsen Q1 Sales Up, Driven by Growth Platforms

    GLOBENEWSWIRE

    Ipsen signs $1.8bn RNA drug alliance with Skyhawk

    PRESS RELEASE

    Ipsen publishes its 2023 Universal Registration Document

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.